Zepbound and sleep apnea: reading the SURMOUNT-OSA evidence

What the two sleep-apnea trials measured, how PAP use differed, and why the findings do not justify stopping an existing treatment.

In this guide

Two trials answered related questions

SURMOUNT-OSA ran two 52-week randomized trials in adults with obesity and moderate-to-severe obstructive sleep apnea. One enrolled people not using positive airway pressure (PAP); the other enrolled people using PAP. Participants received tirzepatide or placebo. The separate populations prevent a simple reading that medication universally replaces a PAP device.

Understand the measurement before the percentage

The apnea–hypopnea index (AHI) counts episodes of stopped or reduced breathing per hour of sleep. At week 52, trial 1 reported changes of −25.3 events/hour with tirzepatide and −5.3 with placebo, a between-group difference of −20.0. Trial 2 reported −29.3 and −5.5, respectively, a difference of −23.8. These are mean changes, not a guarantee that any individual’s sleep apnea resolves.

What FDA approved

FDA approved Zepbound in December 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity, used with a reduced-calorie diet and increased physical activity. The announcement describes two trials totaling 469 adults without type 2 diabetes. This indication is more specific than snoring, poor sleep or suspected sleep apnea; a diagnosis and individualized treatment assessment matter.

Do not use a trial summary to change PAP on your own

A better average AHI is not the same as proof that you no longer need a prescribed device. Bring the evidence to the clinician managing your sleep apnea and ask how effectiveness will be reassessed. The study does not supply a personal stopping rule. A change in weight, symptoms or medication should be discussed within your existing sleep-care plan.

Keep adverse effects and practical limits visible

FDA identifies gastrointestinal effects among the common adverse reactions and describes important warnings and contraindications. A treatment discussion needs current labeling and your medical history, not just the trial’s primary outcome. The approval belongs to the specified product and population; it is not evidence that a different preparation or an online provider produces the same results.

Questions for a service offering treatment

Ask who will coordinate with your sleep specialist, what records are needed, how follow-up works, and which fees are separate. Obtain a medication quote and confirm insurance requirements directly. Provider reviews can help compare those services, but they cannot diagnose sleep apnea or determine whether the medicine is appropriate. Keep the clinical decision separate from the price comparison.

Put the questions to work

Compare our researched providers or build your provider checklist.

Explore relevant provider reviews

Use these reviews to compare the published services and terms. Inclusion is a research starting point, not a recommendation for treatment.

Continue your research

Sources & scope

Sources checked October 12, 2026. This guide explains published information and consumer research questions; it is not a clinical evaluation.

  1. SURMOUNT-OSA randomized trials
  2. FDA: Zepbound approval for obstructive sleep apnea

Prices and terms can change. Confirm your specific offer directly with the provider.

Before you go, compare one more option.